TY - JOUR
T1 - Favorable modifiable cardiovascular risk profile is associated with lower healthcare costs among cancer patients
T2 - The 2012-2013 medical expenditure panel survey
AU - Singh, Jai
AU - Valero-Elizondo, Javier
AU - Salami, Joseph A.
AU - Warraich, Haider J.
AU - Ogunmoroti, Oluseye
AU - Spatz, Erica S.
AU - Desai, Nihar
AU - Rana, Jamal S.
AU - Virani, Salim S.
AU - Blankstein, Ron
AU - Blaha, Michael J.
AU - Nasir, Khurram
N1 - Funding Information:
Dr Nasir is on the advisory board for Quest Diagnostics and consultant for Regeneron. Dr Blankstein is on the advisory board for Amgen Inc, is a consultant to EKOS Corporation, and receives research support from Amgen Inc and Gilead Inc. Dr Desai and Dr Spatz are supported by grant K12 HS023000-01 from the Agency for Healthcare Research and Quality. Dr Desai receives research funding from the Centers for Medicare & Medicaid Services to develop and maintain performance measures that are used for public reporting and support from Johnson & Johnson and Medtronic, through Yale University, to develop methods of clinical trial data sharing. Dr Spatz receives research funding from the Centers for Medicare & Medicaid Services to develop and maintain performance measures that are used for public reporting. The remaining authors have no disclosures to report.
Publisher Copyright:
© 2018 The Authors.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Background--Atherosclerotic cardiovascular disease (ASCVD) and cancer are among the leading causes of economic burden, morbidity, and mortality in the United States. We aimed to quantify the overall impact of cardiovascular modifiable risk factor (CRF) profile on healthcare expenditures among those with and without ASCVD and/or cancer. Methods and Results--The 2012-2013 Medical Expenditure Panel Survey, a nationally representative adult sample (≥40 years), was utilized for the study. Variables included ASCVD, CRF (hypertension, diabetes mellitus, hypercholesterolemia, smoking, physical activity and/or obesity), and cancer (all). Two-part econometric models analyzed cost data. Medical Expenditure Panel Survey participants (n=27 275, 59±9 years, 52% female) were studied and 14% had cancer, translating to 25.6 million US adults over 40 years of age. A higher prevalence of ASCVD was noted in those with versus without cancer (25% versus 14%). Absence of ASCVD and a more favorable CRF profile were associated with significantly lower expenditures across the spectrum of cancer diagnosis. Among cancer patients, the adjusted mean annual cost for those with and without ASCVD were $10 852 (95% confidence interval [8917, 12 788]) and $6436 (95% confidence interval [5531, 7342]). Among cancer patients without ASCVD, adjusted annual healthcare expenditures among those with optimal versus poor CRF profile were $4782 and $7256. Conclusions-In a nationally representative US adult population, absence of ASCVD and a favorable CRF profile were associated with significantly lower medical expenditure among cancer patients. This provides estimates to continue better cardiovascular management and prevention practices, while contextualizing the burden of cancer.
AB - Background--Atherosclerotic cardiovascular disease (ASCVD) and cancer are among the leading causes of economic burden, morbidity, and mortality in the United States. We aimed to quantify the overall impact of cardiovascular modifiable risk factor (CRF) profile on healthcare expenditures among those with and without ASCVD and/or cancer. Methods and Results--The 2012-2013 Medical Expenditure Panel Survey, a nationally representative adult sample (≥40 years), was utilized for the study. Variables included ASCVD, CRF (hypertension, diabetes mellitus, hypercholesterolemia, smoking, physical activity and/or obesity), and cancer (all). Two-part econometric models analyzed cost data. Medical Expenditure Panel Survey participants (n=27 275, 59±9 years, 52% female) were studied and 14% had cancer, translating to 25.6 million US adults over 40 years of age. A higher prevalence of ASCVD was noted in those with versus without cancer (25% versus 14%). Absence of ASCVD and a more favorable CRF profile were associated with significantly lower expenditures across the spectrum of cancer diagnosis. Among cancer patients, the adjusted mean annual cost for those with and without ASCVD were $10 852 (95% confidence interval [8917, 12 788]) and $6436 (95% confidence interval [5531, 7342]). Among cancer patients without ASCVD, adjusted annual healthcare expenditures among those with optimal versus poor CRF profile were $4782 and $7256. Conclusions-In a nationally representative US adult population, absence of ASCVD and a favorable CRF profile were associated with significantly lower medical expenditure among cancer patients. This provides estimates to continue better cardiovascular management and prevention practices, while contextualizing the burden of cancer.
KW - Cancer
KW - Cardiovascular disease risk factors
KW - Cost
UR - http://www.scopus.com/inward/record.url?scp=85046441916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046441916&partnerID=8YFLogxK
U2 - 10.1161/JAHA.117.007874
DO - 10.1161/JAHA.117.007874
M3 - Article
C2 - 29686026
AN - SCOPUS:85046441916
SN - 2047-9980
VL - 7
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 9
M1 - e007874
ER -